icosapent ethyl
AssetAlso AMR101, Ethyl Icosapentate, Icosapent Ethyl Oral Capsule, NSC-759597
Ethyl ester of eicosapentaenoic acid that lowers triglyceride levels
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 8
- Indications
- 22
- Trials
- 3
- Developers
Indications
8Angina, Unstable
Approved, accessdata.fda.gov, 7 Oct 2026
Cardiovascular disease
Approved, accessdata.fda.gov, 7 Oct 2026
Diabetes mellitus
Approved, accessdata.fda.gov, 7 Oct 2026
5 more
In the full profile
- Targets and what it contains2
- Owner and partners3
- Trials22
- Evidence for its targets3
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.